If experts fully understand the mechanisms that cause Long covid19then they might be able to help the patients In a monoclonal antibody, following a clinical study, says Associate Professor of Health and Epidemiology, Gikas Mayorkinis.
In an interview with the FM agency, Gikas Mayorkinis even says that Long Covid now seems to have a lesser impact than in the early waves of crown for patients, however, as he points out, it causes a fairly significant number of people.
“The problems it creates can concern neurological symptoms, breathing difficulty, fatigue, etc. Long Covid causes a significant degree of difficulty in everyday life for some people who can keep away from work and unfortunately, we do not have many tools to deal with. We, here, at the University, participate in a European study along with Spain, France, Italy, and Croatia, where we are researching what is causing Long Covid. And if we understand some of the mechanisms, then we may be able to offer a more special help to the sufferers. “
The answer is likely to be in a monoclonal antibody
“Our basic finding, which we saw in patients sticking to Covid19, is that some parts of our DNA, our genome are activated, which we have seen activated in patients with neurological diseases, such as multiple sclerosis,” says the professor to add to him, ” for the nerves. This is one of our key objects and what we have found in this study is that this protein needs very special conditions to study and measure. It is unstable and within 6 to 7 weeks a fairly laborious analysis should be completed that is currently specialized, only in a laboratory in the world in Lyon. ” If you find the mechanism that works all this, you will find the medicine, the teacher is reasonably asked.
“If it is found that this protein is actually increased in patients with long covid, it is possible to intervene with a monoclonal antibody attacking this protein. Theoretically it could, because there are such preparations, but which have not yet been licensed and will need a clinical trial. If it actually verifies, then a second -stage clinical trial could be done to see if this treatment we have in our minds can help these patients. “
As Mr Mayorkinis explains, the study has begun for three years and will continue at least two.
“We are on the alert for a stronger exacerbation – Epidemiological lullaby”
Concerning the epidemiological situation at this stage, the distinguished clinical Iologist states:
“We are on the alert, because usually after a long-term recession of Covid-19 we have a stronger exacerbation. We are waiting to see if the “lullaby” that began in November 2024 (which has not happened before) will continue, or we will see again a great rise in the summer, as we usually notice in recent years. The fact that we have not seen any uplifting for several months has been worried about us, because it is very likely to happen in the summer months. The data, for Nimbus, as his nickname has come out, on the internet, show that he may be the candidate who will lead the summer exacerbation, but we can still not know 100%. There are reports from some Asian countries (China, Hong Kong, Singapore) that the cases were increased, and this was due to this variant. In Europe, we still have a moderate number of outbreaks. Epidemiological surveillance in different parts of the world sees this particular variant, which comes from Omikron, gradually rise. It is still being investigated if it escapes the immune system better than other variants, or if its transmission changes. “
Intense sore throat and cough
The symptomatology of this variant has some differences from what we already know, is then asked by Mr. Majorkinis. “Empirical references from various doctors who have not undergone statistical processing speak of intense sore throat and cough and not so often the classic gathering that we have seen in recent years.”
Is this variant visible in tests? Because last year there were reports that while doctors clinically found COVID19, the tests were negative, it is the next question asked by Professor Mayorkin.
“It has been reported at times that the test is falsely negative. But we have no reports that the variant is not detected by the tests that are in principle molecular and then the rapids, which the truth is that they are more sensitive to not showing the infection. However, because all rapid targets an area of the genome of the virus, which is not too much, we have not seen large fluctuations between different strains. It is not clear that we have a problem that this particular variant from the tests we have currently available will not be detected. “
source: Iatropedia.gr